Search

Zentalis Pharmaceuticals Inc

Lezárt

3.03 -1.62

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.99

Maximum

3.1

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+182.96% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

335K

331M

Előző nyitás

4.65

Előző zárás

3.03

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 21. 23:56 UTC

Revvity Inc is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 21. 23:56 UTC

Correlated Moves

Eversource Energy is advancing in after-market hours, influenced by OGE Energy's gains earlier in the session, though it remains below its 20-day moving average.

2026. szept. 21. 23:56 UTC

Owens Corning is trading modestly higher in after-market hours, recovering from a recent trend of six consecutive sessions ending lower.

2026. szept. 21. 23:56 UTC

Ameriprise Financial Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

2026. szept. 21. 23:56 UTC

Pool Corp is trading modestly higher in after-market hours following a decline in the Chicago Fed National Activity Index for August, reflecting slower economic growth.

2026. szept. 21. 23:55 UTC

Chimera Investment Corp is trading roughly flat in after-market hours, about 2.48% below its 20-day moving average.

2026. szept. 21. 23:55 UTC

Lamb Weston Holdings Inc is trading modestly lower in after-market hours, continuing the earlier session's weakness and remaining below its 20-day moving average.

2026. szept. 21. 23:55 UTC

Ziff Davis Inc declined during after-market hours on Monday, influenced by broader economic slowdown signals, despite remaining above its 20-day moving average.

2026. szept. 21. 23:55 UTC

Old Republic International Corp is trading modestly higher in after-market hours, recovering slightly after a series of declines over the previous five sessions.

2026. szept. 21. 23:55 UTC

Carlyle Group Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 21. 23:55 UTC

Mitek Systems Inc is up in after-market trading, reaching a peak despite remaining below its 20-day moving average amid slowing economic growth signals.

2026. szept. 21. 23:55 UTC

Truist Financial Corp is declining in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. szept. 21. 23:55 UTC

Darling Ingredients Inc's stock is trading modestly higher in after-market hours, despite a decline in the Chicago Fed National Activity Index for August.

2026. szept. 21. 23:55 UTC

Solaredge Technologies Inc is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 21. 23:55 UTC

Booking Holdings Inc. is trading modestly higher in after-market hours following Monday's close, despite remaining significantly below its 20-day moving average.

2026. szept. 21. 23:55 UTC

OraSure Technologies Inc. is trading modestly higher in after-market hours, marking its eighth consecutive session of gains while remaining above its 20-day moving average.

2026. szept. 21. 23:55 UTC

Revolve Group Inc. is trading roughly flat in after-market hours, fluctuating within a range amid economic growth concerns from the Chicago Fed National Activity Index.

2026. szept. 21. 23:52 UTC

News

Boeing Co. has secured two defense contracts worth $41.5 million, while shares have declined slightly in after-market trading, remaining near the lower end of their one-month range.

2026. szept. 21. 23:52 UTC

Yelp Inc. is declining in after-market trading, remaining significantly below its 20-day moving average and continuing a trend of lower daily closes.

2026. szept. 21. 23:51 UTC

Cathay General Bancorp is trading modestly higher in after-market hours, recovering from a slight dip and reaching a peak cumulative return of nearly 1%.

2026. szept. 21. 23:51 UTC

Janus International Group Inc has advanced modestly in after-market trading, continuing a pattern of strength observed throughout the session.

2026. szept. 21. 23:51 UTC

CoStar Group Inc rebounded in after-market trading, showing a cumulative return above its prior close despite remaining below its 20-day moving average.

2026. szept. 21. 23:51 UTC

Cooper Companies Inc is trading modestly higher during after-market hours, despite a significant decline over the past month and trading below its 20-day moving average.

2026. szept. 21. 23:51 UTC

Social Media

Rocket Lab Corp's stock rises in after-market trading following Cantor Fitzgerald's bullish note, reiterating a $122 price target amid successful launches and an upcoming acquisition.

2026. szept. 21. 23:51 UTC

Cabaletta Bio Inc saw notable gains in after-market trading, recovering from a low return shortly after the market closed to a higher return by late session.

2026. szept. 21. 23:51 UTC

Molson Coors Beverage Co sees a modest increase in after-market trading, reaching its highest cumulative return since Monday's close, despite being below its 20-day moving average.

2026. szept. 21. 23:51 UTC

Allstate Corp is seeing notable upward movement in after-market trading, recovering from six consecutive sessions of lower finishes.

2026. szept. 21. 23:51 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. szept. 21. 23:51 UTC

OGE Energy Corp is trading modestly higher in after-market hours, following notable upward movement from its previous close, despite remaining below its 20-day moving average.

2026. szept. 21. 23:51 UTC

United Therapeutics Corp is trading modestly higher in after-market hours, recovering from an initial dip and showing volatility since Monday's close.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

182.96% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.8 USD  182.96%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.